Clinical Trial Update: Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating neoadjuvant regorafenib in combination with nivolumab and short-course radiotherapy for stage II–III rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Stivarga (regorafenib)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Rectal Cancer Stage II, Rectal Cancer Stage III | Phase 2 | Status: ACTIVE_NOT_RECRUITING